Share story
Capital AI

Iambic Therapeutics files for Nasdaq IPO

AI-assisted drug developer Iambic Therapeutics filed for an initial public offering and applied to list on the Nasdaq Global Select Market under the symbol IAM. The preliminary prospectus does not specify the number of shares, price range or expected proceeds. Iambic combines predictive AI models with automated chemistry and biology experiments to select and optimize drug candidates. Its lead program, IAM1363, is in a Phase 1/1b trial for HER2-altered solid tumors, while two other programs remain preclinical. The company cautioned that its platform has not produced an approved drug.
Sources
SEC EDGAR
Published by Tech & Business, a media brand covering technology and business. This story was sourced from SEC EDGAR and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital Infrastructure
Capital Infrastructure

Rainmaker raises $100 million to scale measured cloud seeding

Cloud-seeding startup Rainmaker raised $100 million in a Series B backed by NOA VC, Upfront Ventures, DCVC, Lowercarbon Capital and Dream Ventures. The company plans to expand its weather-research team, scale operations in the Ame...

ventureburn.com
Infrastructure Products
Infrastructure Products

Amazon commits $20 million to Colorado River conservation effort

Amazon launched a Colorado River Basin Collaborative and committed $20 million to it, with a goal of raising $100 million over two years for conservation projects. Participating companies may contract independently with projects v...

The Verge
Security
Security

Greenberg Traurig clients sue over data breach

A proposed class of Greenberg Traurig clients has sued the law firm in New York federal court, alleging that it failed to protect their personal information before a preventable data breach. The plaintiffs also allege that the fir...

Law360